It is evident that PPAR-γ agonists, including pioglitazone, are known to counteract the characteristics of diabetes and hypertension, activating via production of adiponectin which is mediator moderating oxidative stress through activation of signaling cascades, such as cAMP–PKA and AMPK–eNOS component [39] and reduction in sensitivity to Ang II [11] respectively. The gene discussed is ADIPOQ; the disease is diabetes mellitus.